Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

se-free survival of AML patients by more than 50%. Importantly, this significant therapeutic benefit was achieved with a remarkably well-tolerated, self-administered immunotherapy."

EpiCept's MAA submission for Ceplene is being assessed under the EU centralized procedure, and if approved, will provide a marketing authorization valid in all EU member states, along with Iceland, Liechtenstein and Norway. The European Commission has previously granted orphan drug status to Ceplene for use in the treatment of AML. If the application for Ceplene continues to follow usual EU regulatory timelines, the next milestone on Ceplene's path to approval is expected to be the CHMP Day 180 list of outstanding issues, which EpiCept expects will be received in the fourth quarter of 2007. EpiCept expects this to be followed by a recommendation regarding approvability from the CHMP and a final decision by the European Commission during the first half of 2008.

About Ceplene

Ceplene is EpiCept's registration-stage compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

About Acute Myeloid Leukemia (AML)

AML is the most common form of acute leukemia in adults. There are approximately 47,000 AML patients in the EU, with 14,000 new cases occurring each year. For the majority of AML patients, the prospects for long-term survival are disappointing. Once diagnosed with AML, patients are treated with toxic chemotherapies. Although approximately 75% of patients achieve a complete remission, the leukemia frequently recurs (a "relapse"), usually within 1-2 years. Despite follow-up treatment that may include very toxic chemotherapy or bone marrow transplantation, only 10% to 20% of patients survive l
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... CHAPEL HILL, N.C. , May 17, 2013 ... on how organizations communicate internally. Faced with a ... adjust their strategies and tactics for communicating with ... the effectiveness of all the strategies, tactics and ... In a new study, Best ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- United Medical Education, a company that ... Pediatric Advanced Life Support (PALS) and Basic Life Support ... ACLS online course manuals. In order to gain ... build an account with the company. By offering the ... Medical Education is setting a precedent among similar companies. ...
(Date:5/17/2013)... /PRNewswire-iReach/ -- The escalation of new biological drugs, ... emphasis on alternate delivery technologies. Alternate delivery technologies ... factors are converging to create both risk ... device partners . These include new classes of ... toward self-administration for chronic diseases, shifting patient demographics ...
Breaking Medicine Technology:Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 2Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 3Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 4Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 5Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 6Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 7Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 8Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 9Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 10Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 11Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 12Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 13Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 14Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 15Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 16Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 17Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 18Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 19Volcano Reports 44 Percent Increase in Fourth Quarter Revenues 20FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 2FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 3FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 4FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 5FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 6FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 7FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 8FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 9FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 10FTC Bars Transitions Optical, Inc. from Using Anticompetitive Tactics to Maintain its Monopoly in Darkening Treatments for Eyeglass Lenses 11
(Date:5/18/2013)... 6Webs.com is the leader in ... and comprehensive comparisons make 6Webs.com the useful resource consumers ... just recently finished conducting their assessments of the leading ... from 6Webs.com reports, "There has been an increase interest ... of use, expandability and mobility. Combine these features with ...
(Date:5/18/2013)... Houston, TX (PRWEB) May 18, 2013 Show ... many years of various different training systems that is all ... possible has caught the attention of http://ShowAndGoTrainingReview.com ’s ... Go Training is a unique “four phase system” designed ... the minimum amount of time spent working out in the ...
(Date:5/18/2013)... 2013 The California College of Ayurveda ... the Ayurvedic Spa , the client receives stress ... and lifestyle recommendations and stress management techniques by ... is the traditional healthcare system of India. It is ... is the basis for all optimum health. Ayurveda believes ...
(Date:5/18/2013)... 18, 2013 The American Society ... A. Kitzhaber, M.D., (D) to sign a bill (HB ... minors under the age of 18 from tanning indoors. ... third state in the nation to enact an under-18 ... indoor tanning bans for minors. Nationwide, 34 states and ...
(Date:5/18/2013)... Dr. Robert Tracey, an area leader in dental laser ... of the root causes of sleep apnea to provide and ... Sleep Month, Dr. Tracey points out estimates revealing that 40 ... sleep apnea is one of the most common of all. ... breathing at different times while sleeping. When this happens, the ...
Breaking Medicine News(10 mins):Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 2Health News:Pomona, NY Dentist, Dr. Robert Tracey of General & Laser Assisted Dentistry (GLAD) Highlights Sleep Apnea Dentistry Services for Better Sleep Month 3
... whether people were scanned or not , , FRIDAY, Feb. 6 ... low back pain that has no apparent underlying cause doesn,t ... that doctors should not conduct routine MRI, CT or radiography ... authors say. , Dr. Roger Chou, of the Oregon Health ...
... for Palliative Medicine,s Fellowship Program received full accreditation from ... the first accredited fellowship program in palliative medicine in ... Hospice, The Institute for Palliative Medicine has trained fellows ... is known as one of the most clinically demanding ...
... Scientists at Melbourne,s Burnet Institute have developed a potential ... which described the invention, has recently been published in ... Investigation . , Head of the Burnet Institute,s ... his group has produced a monoclonal antibody to a ...
... This release is available in Spanish . ... fundamental role in the prognosis of acute lymphoblastic leukemia as ... of research involving a team made up of specialists from ... Medical Research at the same University of Navarra, as well ...
... Deal Reflects Steady Progress in Expanding Reach Across ... Food IndustryMUNDELEIN, Ill., Feb. 6 Z Trim ... multi-functional food ingredients, has agreed to an exclusive ... a company engaged in the supply of various ...
... 6 Abbott ( NYSE: ABT ),today announced that ... 1976 (HSR) applicable to Abbott,s cash tender offer to,purchase ... Advanced Medical,Optics (AMO) expired last night at 11:59 p.m. ... of the HSR waiting period satisfies one of the ...
Cached Medicine News:Health News:Imaging of Low Back Pain Fails to Change Outcomes 2Health News:San Diego Medical Community Receives First-Ever Accredited Palliative Medicine Fellowship Program 2Health News:San Diego Medical Community Receives First-Ever Accredited Palliative Medicine Fellowship Program 3Health News:New treatment hope for prostate cancer 2Health News:New genes involved in acute lymphoblastic leukemia play fundamental role in prognosis of the disease 2Health News:Z Trim to be Distributed in Israel by Freya ICB 2Health News:Z Trim to be Distributed in Israel by Freya ICB 3Health News:Z Trim to be Distributed in Israel by Freya ICB 4Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 2Health News:Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review 3
... TowerPack is an innovative, quick and ... Tips. Use 60% less space on ... plastic. With this amazingly easy-to-use, one-hand ... for the whole range of Diamond ...
10 L, Racked, 96 tips/rack Extended length pipette tips recommended for 5 and 10 L pipettes....
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 ul reference mark make it ideal for low volume pipetting....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: